Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H12N2O4S2 |
Molecular Weight | 240.3 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O
InChI
InChIKey=LEVWYRKDKASIDU-IMJSIDKUSA-N
InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1
Molecular Formula | C6H12N2O4S2 |
Molecular Weight | 240.3 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB00138Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7276953 | https://www.ncbi.nlm.nih.gov/pubmed/27306219 | https://www.ncbi.nlm.nih.gov/pubmed/28297659
Sources: https://www.drugbank.ca/drugs/DB00138
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7276953 | https://www.ncbi.nlm.nih.gov/pubmed/27306219 | https://www.ncbi.nlm.nih.gov/pubmed/28297659
Cystine is the oxidized dimer form of the amino acid cysteine. Cystine serves two biological functions, a site of redox reactions and a mechanical linkage that allows proteins to retain their 3-dimensional structure. It is common in many foods such as eggs, meat, dairy products, and whole grains as well as skin, horns and hair. Human hair and skin contain approximately 10–14% cystine by mass. Cysteine supplements are sometimes marketed as anti-aging products with claims of improved skin elasticity. Cysteine is more easily absorbed by the body than cystine, so most supplements contain cysteine rather than cystine. N-acetyl-cysteine (NAC) is better absorbed than other cysteine or cystine supplements.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075149 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28070112 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Infrared analysis of urinary calculi by a single reflection accessory and a neural network interpretation algorithm. | 2001 |
|
Capture and identification of folding intermediates of cystinyl proteins by cyanylation and mass spectrometry. | 2001 |
|
Blood glutathione and cysteine concentrations in twin children. | 2001 Apr |
|
Histological and histochemical observations in the stomach of the Senegal sole, Solea senegalensis. | 2001 Apr |
|
Assignment of the disulfide bonds of huwentoxin-II by Edman degradation sequencing and stepwise thiol modification. | 2001 Apr |
|
Determination by liquid chromatography of free and total cysteine in human urine in the form of its S-quinolinium derivative. | 2001 Apr 13 |
|
xCt cystine transporter expression in HEK293 cells: pharmacology and localization. | 2001 Apr 20 |
|
Hounsfield unit density in the determination of urinary stone composition. | 2001 Aug |
|
An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin. | 2001 Aug |
|
Urinary sulfur compounds in Down syndrome. | 2001 Aug |
|
Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. | 2001 Aug |
|
Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. | 2001 Aug 10 |
|
The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. | 2001 Aug 15 |
|
Location and mechanism of alpha 2,6-sialyltransferase dimer formation. Role of cysteine residues in enzyme dimerization, localization, activity, and processing. | 2001 Aug 3 |
|
Solution structure of the satiety factor, CART, reveals new functionality of a well-known fold. | 2001 Aug 7 |
|
[Cystine lithiasis: physiopathology and medical treatment]. | 2001 Feb |
|
A DNA polymerase with specificity for five base pairs. | 2001 Feb 28 |
|
The amino acid transport system b(o,+) and cystinuria. | 2001 Jan-Mar |
|
Thermosipho geolei sp. nov., a thermophilic bacterium isolated from a continental petroleum reservoir in Western Siberia. | 2001 Jul |
|
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. | 2001 Jul |
|
Medical and surgical therapy of the cystine stone patient. | 2001 Jul |
|
Metabolism of S-nitrosoglutathione by endothelial cells. | 2001 Jul |
|
Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. | 2001 Jul 1 |
|
Role of the cystine-knot motif at the C-terminus of rat mucin protein Muc2 in dimer formation and secretion. | 2001 Jul 1 |
|
Hyperglycemia in diabetic rats reduces the glutathione content in the aortic tissue. | 2001 Jul 20 |
|
Cystinuria in the dog: clinical studies during 14 years of medical treatment. | 2001 Jul-Aug |
|
Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. | 2001 Jul-Aug |
|
Configuration and racemization determination of cysteine residues in peptides by chiral derivatization and HPLC: application to oxytocin peptides. | 2001 Jun |
|
Effect of fudosteine, a new cysteine derivative, on mucociliary transport. | 2001 Jun |
|
Estimation of the total sulfur amino acid requirement and the effect of betaine in diets deficient in total sulfur amino acids for the weanling pig. | 2001 Jun |
|
Partial restoration of lutropin activity by an intersubunit disulfide bond: implications for structure/function studies. | 2001 Jun |
|
Self-assembling, cystine-derived, fused nanotubes based on spirane architecture: design, synthesis, and crystal structure of cystinospiranes. | 2001 Jun 20 |
|
Monitoring of the subtraction process in solid-phase representational difference analysis: characterization of a candidate drug. | 2001 Jun 27 |
|
Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. | 2001 Jun 6 |
|
Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor. | 2001 Mar |
|
Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. | 2001 Mar |
|
Occurrence of the Asn45Ser mutation in the GPIX gene in a Belgian patient with Bernard Soulier syndrome. | 2001 Mar |
|
Disulfide bond structure of the AVR9 elicitor of the fungal tomato pathogen Cladosporium fulvum: evidence for a cystine knot. | 2001 Mar 27 |
|
Molecular cloning of preproinsulin cDNAs from several osteoglossomorphs and a cyprinid. | 2001 Mar 28 |
|
[Leber's hereditary optic neuropathy]. | 2001 Mar-Apr |
|
Extracorporeal shock wave lithotripsy in children. Efficacy, complications and long-term follow-up. | 2001 May |
|
A new strategy for the synthesis of cyclopeptides containing diaminoglutaric acid. | 2001 May |
|
The metabolism of sulphur in relation to the biochemistry of cystine and cysteine: its fundamental importance in biology. A cyclic interchange between their mono- and di-sulphides is the unique reaction creating life and intelligence. | 2001 May |
|
Energy utilization of low-protein diets in growing pigs. | 2001 May |
|
Synthetic peptides derived from the beta2-beta3 loop of Raphanus sativus antifungal protein 2 that mimic the active site. | 2001 May |
|
Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. | 2001 May |
|
Human cystinuria-related transporter: localization and functional characterization. | 2001 May |
|
Design of Gram-negative selective antimicrobial peptides. | 2001 May 15 |
|
Synthesis of diaminosuberic acid derivatives via ring-closing alkyne metathesis. | 2001 May 18 |
|
Pediatric urolithiasis in Armenia: a study of 198 patients observed from 1991 to 1999. | 2001 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27306219
The subjects in the C/T group were orally administered an amino acid supplement, which contained 700 mg cystine and 280 mg theanine (total weight, 1.7 g; Ajinomoto, Tokyo, Japan), once a day starting 1 week before and ending at the same time as the administration of S-1 (a total of 35 days)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28297659
200,000 hTERT-HME cell were plated in 6-well plates and switched to cystine-deprived media for 12 hr prior to FACS analysis. CMDCFDA and C11-BODIPY581/591 (Molecular Probes; Thermo Fisher) were used to detect total and lipid ROS, respectively. Following deprivation of cystine for 12 hr, cells were washed with PBS, loaded with either CMDCFDA (10 mM) or C11 BODIPY (2 mM) in DPBS for 30 min, trypsinized with 0.25% Trypsin-EDTA, resuspended inPBSwith1%FBS, and analyzed using an AttuneNxT flow cytometer (Thermo Fisher). Dyes were excited using a blue 488-nm laser, and emission was recorded on BL1 (530/30) for a minimum of 5,000 cells per sample.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:04:02 GMT 2023
by
admin
on
Sat Dec 16 18:04:02 GMT 2023
|
Record UNII |
48TCX9A1VT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
27027-2
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
22687-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
13371-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
12469-3
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
DSLD |
2409 (Number of products:212)
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
34278-2
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
DSLD |
76 (Number of products:12)
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2180-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
26843-3
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
25894-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
32169-5
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2179-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
14686-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
33872-3
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
10969-4
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
16709-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
13966-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
44312-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
53080-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
27350-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
21056-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2175-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
32237-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
32238-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
30065-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
32138-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2177-4
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
9644-6
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
56677-8
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
16711-4
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
22728-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2178-2
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
26962-1
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
13725-7
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
2176-6
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
22672-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
22653-0
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
||
|
LOINC |
13394-2
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D003553
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
1161586
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
DB00138
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
SUB01541MIG
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
DTXSID2046418
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
CYSTINE
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
4130
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
13203
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
m4049
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
16283
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
3036
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000091082
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
48TCX9A1VT
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
48TCX9A1VT
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
C29610
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
17376
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
67678
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
200-296-3
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
SUB41569
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
35491
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
56-89-3
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
50058
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL590540
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY | |||
|
7922
Created by
admin on Sat Dec 16 18:04:03 GMT 2023 , Edited by admin on Sat Dec 16 18:04:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
INHIBITOR OF AGGREGATION->TARGET | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
Natural substrate for transporter responsible for enhancing the synthesis of GSH by bringing cystine into cell. Inhibition leads ferroptosis.
|
||
|
INHIBITOR -> TARGET |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |